AzTrials
AzTrials

AnxietyNCT05417412

Video-visit Behavior Therapy for Anxiety and Depression in Youth

A study testing Brief Behavioral Therapy in people with Anxiety and Depression, run by San Diego State University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This project focuses on adapting and pilot testing an efficacious brief behavioral therapy (STEP-UP) for youths with anxiety or depression to be delivered as a telehealth intervention by clinic staff in low-resource community health centers (CHCs). Read more about this study

Who is it for?
Ages 8 to 17 years
Conditions the study is for
Anxiety, Depression
What is being tested?
Brief Behavioral Therapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
12 participants
Where
1 siteUnited States
Study dates
2 Aug 2021to 30 Jul 2023
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 8 to 17 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Youth is a patient at a participating community health center (CHC) site
  • Youth is clinically referred by a provider and / or has anxiety and / or depression as a diagnosis or target problem in their medical record
  • Youth is in the physical and legal custody of the caretaker and is not currently involved in the foster care system
  • Youth is able and willing to conduct study assessments and intervention sessions in English
  • Primary caretaker is able and willing to conduct study assessments and intervention sessions in English or in Spanish
  • Youth is functioning at or above the academic level of a typical 8-year-old child (i.e., placed in at least the second-grade level school across all subjects in a general education classroom)
  • Primary caretaker agrees that focusing on anxiety and / or depression would be a useful primary target for treatment
  • Youth has clinically significant symptoms of anxiety and / or depression by youth or caretaker report

Who cannot join

  • Youth is receiving an alternate intervention for anxiety or depression
  • Youth or parent reports that the youth is experiencing active suicidal ideation with plan or intent (i.e., within last three months) and / or has made a suicide attempt within the last six months
  • Youth or parent reports that the youth is currently engaging in non-suicidal self-injury (i.e., within last three months)
  • Youth or parent reports that the youth has experienced recent physical or sexual abuse (i.e., within last three months).

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Kaiser Permanente Northwest Center for Health Research

    Portland, Oregon, 97227

Other trials in United States

About this study

This project focuses on adapting and pilot testing an efficacious brief behavioral therapy (STEP-UP) for youths with anxiety or depression to be delivered as a telehealth intervention by clinic staff in low-resource community health centers (CHCs).

Conditions
Anxiety, Depression
Being tested
Brief Behavioral Therapy
Keywords
Child, Adolescent
Medical subject headings
Anxiety Disorders, Depression

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Brief Behavioral TherapyBehavioural

    Also called STEP-UP, BBT

    8-12 sessions of brief behavioral therapy administered by behavioral health / mental health staff at participating community health centers (CHCs)

Study groups in NCT05417412
Study groupRoleWhat they receive
STEP-UP (brief behavioral therapy)ExperimentalIntervention arm of open trial
Receives: Behavioral: Brief Behavioral Therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Minimum Attendance

    Receipt of a minimum dose of intervention. A minimum dose was defined as 8 or more sessions of the intervention.

    Measured: Week 16 (post-intervention)

  2. Client Satisfaction Scale - Parent (CSQ-8-P)

    Parent ratings of satisfaction with the intervention. Ratings of "mostly" or "very" satisfied were coded as "satisfied." All other ratings were coded as "unsatisfied."

    Measured: Week 16 (post-intervention)

  3. Client Satisfaction Scale - Child (CSQ-8-C)

    Youth ratings of satisfaction with the intervention. Ratings of "mostly" or "very" satisfied were coded as "satisfied." All other ratings were coded as "unsatisfied."

    Measured: Week 16 (post-intervention)

  4. Participant Acceptability Questionnaire - Parent (PAQ-P)

    Parent ratings of the acceptability of the telehealth intervention. Responses were classified as "little or no technical problems" or "technical difficulties."

    Measured: Week 16 (post-intervention)

  5. Participant Acceptability Questionnaire - Child (PAQ-C)

    Youth ratings of the acceptability of the intervention. Youths were asked whether they would recommend the intervention to a friend. Responses were included "would recommend" and "unlikely."

    Measured: Week 16 (post-intervention)

Secondary outcomes (8)
  1. Screen for Child Anxiety and Related Disorders - Parent (SCARED-P)

    Total score on the Screen for Anxiety and Related Disorders scale (parent report on youth), a dimensional measure of anxiety symptoms. Scores range from 0 to 82, and higher scores indicate greater symptom severity. Scores >= 25 may indicate the presence of an anxiety disorder.

    Measured: Week 16 (post-intervention)

  2. Screen for Child Anxiety and Related Disorders - Child (SCARED-C)

    Total score on the Screen for Anxiety and Related Disorders scale (youth report on self), a dimensional measure of anxiety symptoms. Scores range from 0 to 82, and higher scores indicate greater symptom severity. Scores >= 25 may indicate the presence of an anxiety disorder.

    Measured: Week 16 (post-intervention)

  3. Mood and Feelings Questionnaire - Parent (MFQ-P)

    Total score on the Mood and Feelings Questionnaire - parent report on youth (MFQ-P) a dimensional measure of depression symptoms. Scores range from 0 to 68, and higher scores indicate greater depression symptom severity.

    Measured: Week 16 (post-intervention)

  4. Mood and Feelings Questionnaire - Child (MFQ-C)

    Total score on the Mood and Feelings Questionnaire (youth report on self) a dimensional measure of depression symptoms. Higher scores indicate greater symptom severity. Scores range from 0 to 66, and higher scores indicate greater depression symptom severity.

    Measured: Week 16 (post-intervention)

  5. Symptom Impairment Scale - Parent (SIS-P)

    Parent rating of child impairment in school, social, and family domains from symptoms of anxiety (3 questions) and depression (3 questions). Higher scores indicate greater levels of perceived impairment. Individual questions scores range from zero (not at all impairing) to three (very much impairing), and the total score ranges from 0 to 18.

    Measured: Week 16 (post-intervention)

  6. Symptom Impairment Scale - Child (SIS-C)

    Youth self-rating of impairment in school, social, and family domains from symptoms of anxiety (3 questions) and depression (3 questions). Higher scores indicate greater levels of perceived impairment. Individual questions scores range from zero (not at all impairing) to three (very much impairing), and the total score ranges from 0 to 18.

    Measured: Week 16 (post-intervention)

  7. Child Avoidance Measure - Parent (CAMP)

    Parent rating of youth avoidance behaviors due to anxiety. Scores range from 0 to 24, and higher scores indicate greater avoidance.

    Measured: Week 16 (post-intervention)

  8. Child Avoidance Measure - Child (CAMP)

    Youth self-report rating of avoidance behaviors due to anxiety. Scores range from 0 to 24, and higher scores indicate greater avoidance.

    Measured: Week 16 (post-intervention)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Jun 2022
  2. Study start2 Aug 2021
  3. Primary completion30 Aug 2022
  4. Study completion30 Jul 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
12 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05417412
Sponsor's protocol ID
R56MH125159
Other IDs
R56MH125159
Status last verified
May 2024
First submitted
9 Jun 2022
Last updated
16 May 2024
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Brief Behavioral Therapy in people with Anxiety and Depression, run by San Diego State University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 16 May 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Minimum Attendance (time frame: Week 16 (post-intervention)). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 May 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in